Press Releases
Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
12/15/14Collegium Pharmaceutical Submits New Drug Application for Xtampza™ ER (oxycodone extended-release); Its Abuse-Deterrent, Extended-Release Analgesic for the Treatment of Chronic Pain
Canton, MA – December 15, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration (FDA) seeking authorization to market Xtampza™ ER, its oxycodone extended-release (ER), abuse-deterrent analgesic utilizing the Company’s proprietary DETERx® technology platform. The abuse-deterrent properties incorporated... 
Printer Friendly Version
11/25/14Collegium Pharmaceutical’s CEO to Present at the 26th Annual Piper Jaffray 2014 Healthcare Conference in New York on December 3, 2014
Canton, MA – November 25, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO, Michael Heffernan, will present the Company’s corporate overview on Wednesday, December 3, 2014 at 2:50pm EDT at the 26th Annual Piper Jaffray 2014 Healthcare Conference. The conference will be held at The New York Palace in New York City. The Company’s lead development progr... 
Printer Friendly Version
11/17/14Collegium Pharmaceutical Releases Positive Top-Line Results of Oral Human Abuse Potential (HAP) Study with Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Product
Primary endpoint met in oral abuse potential studyCanton, MA – November 17, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced positive top-line results from its second human abuse potential (HAP) study for Oxycodone DETERx®, its extended-release (ER), abuse-deterrent, oxycodone microsphere-in-capsule product. Oxycodone DETERx®, utilizing Collegium’s DETERx® technology, is designed to be ... 
Printer Friendly Version
10/07/14“Patients with Chronic Pain and Dysphagia (CPD): Unmet Medical Need and Pharmacologic Treatment Options,” Published in Current Medical Research and Opinion
Canton, MA – October 7, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of “Patients with Chronic Pain and Dysphagia (CPD): Unmet Medical Need and Pharmacologic Treatment Options,” in the peer-reviewed medical journal, Current Medical Research and Opinion. Dr. Charles Argoff, an internationally recognized pain specialist and lead author on the publication, stated “This ... 
Printer Friendly Version
09/23/14Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Canton, MA – September 23, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent No. 8,840,928 has been issued by the U.S. Patent and Trademark Office (USPTO). The issued patent covers the DETERx® technology platform. As such, the claims provide broad coverage for all opioids and other drugs prone to abuse that could leverage the DETERx® technology platform. This is the sixth issued U.S. patent related to the DETERx® technology platform and i... 
Printer Friendly Version
08/20/14Collegium Pharmaceutical Announces Publication of Abuse-Deterrent Data on Oxycodone DETERx® in Journal of Opioid Management
Study results support the novel abuse-deterrent properties of Oxycodone DETERx®Canton, MA – August 20, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the publication of the following article, “Impact of physical manipulation on in vitro and in vivo release profiles of Oxycodone DETERx®: An extended-release, abuse-deterrent formulation,” in the Journal of Opioid Management (Volume 10, ... 
Printer Friendly Version
08/07/14Collegium Pharmaceutical Awarded Grant from the NIH to Advance Development of Oxymorphone DETERx®, an Abuse-Deterrent, Extended-Release Product for Chronic Pain
NIH grant supports development of Collegium’s second drug candidate utilizing the DETERx® technology platformCanton, MA – August 7, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that it has been awarded a Phase I, Fast Track Small Business Innovation Research (SBIR) grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to advance development of its Oxymorphone DETERx® program. Upon successful completion of t... 
Printer Friendly Version
08/06/14Collegium Pharmaceutical Announces Positive Top-Line Data from Phase III Study of Oxycodone DETERx®, its Abuse-Deterrent, Extended-Release Product for Chronic Pain
Data Supports 2014 NDA FilingCanton, MA – August 6, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced positive top-line results from its pivotal Phase 3 study of the company’s investigational analgesic Oxycodone DETERx® that studied the treatment of patients with moderate-to-severe chronic low back pain. The study successfully met the primary efficacy endpoint by showing that patients with chronic low back pain treated with Oxycodone DETERx® experienced a... 
Printer Friendly Version
07/02/14Collegium Pharmaceutical Announces Issuance of U.S. Patent Covering Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Opioid Product
Canton, MA – July 2, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent No. 8,758,813 has been issued by the U.S. Patent and Trademark Office (USPTO). The patent relates to Collegium’s Oxycodone DETERx® formulation and contains claims that cover the Company’s lead product, an abuse-deterrent, extended-release oxycodone product utilizing its proprietary DETERx® technology. Collegium currently has six U.S. patents that are Orange Book listab... 
Printer Friendly Version
06/05/14Collegium Announces Poster Presentations for Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Analgesic at the 2014 International Conference on Opioids
Canton, MA – June 5, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the presentation of two scientific posters at the 2014 International Conference on Opioids (ICOO), held in Boston, MA at the Joseph B. Martin Conference Center (Harvard Medical School) from June 8 to June 10. The first poster, titled “Human Abuse Potential Study of Intranasally Administered Oxycodone DETERx®, an Abuse... 
Printer Friendly Version
05/29/14Collegium Pharmaceutical Advances Development Program for Hydrocodone DETERx®, an Abuse-Deterrent, Extended-Release Analgesic for the Treatment of Chronic Pain
Third Opioid Candidate Utilizing the DETERx® TechnologyCanton, MA – May 29, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has identified candidates for its Hydrocodone DETERx® development program. Collegium is currently conducting in vitro testing on these candidates utilizing a robust screening process developed during testing of more advanced products that incorporate the D... 
Printer Friendly Version
05/27/14Collegium Pharmaceutical to Present at the Jefferies 2014 Global Healthcare Conference in New York on June 3, 2014
Canton, MA – May 27, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO, Michael Heffernan, will present the Company’s corporate overview on Tuesday, June 3, 2014 at 8:30am EDT at the Jefferies 2014 Global Healthcare Conference. The conference will be held at the Grand Hyatt in New York City. The Company’s lead development program is Oxycodone DETERx®,... 
Printer Friendly Version
05/13/14Collegium Pharmaceutical’s CEO to Present at the UBS 2014 Global Healthcare Conference in New York on May 21, 2014
Canton, MA – May 13, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that the Company’s President and CEO, Michael Heffernan, will present the Company’s corporate overview on Wednesday, May 21, 2014 at 9:30am EDT at the UBS 2014 Global Healthcare Conference. The conference will be held at the Sheraton New York Times Square Hotel in New York City. The Company’s lead development program ... 
Printer Friendly Version
04/29/14Collegium Pharmaceutical Announces Successful Pre-NDA Meeting with FDA for Oxycodone DETERx®, its Extended-Release, Abuse-Deterrent Product for the Treatment of Chronic Pain
Canton, MA – April 29, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced that it has successfully concluded its pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) regarding Oxycodone DETERx®, its extended-release (ER), abuse-deterrent, oxycodone microsphere-in-capsule product. The purpose of the meeting was to discuss the non-clinical, clinical and Ch... 
Printer Friendly Version
04/02/14Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx® Compared with OxyContin®
Oxycodone DETERx® exhibited superior crush resistanceCanton, MA – April 2, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced positive topline results from a clinical study evaluating the effect of physical manipulation by crushing on Oxycodone DETERx®, it’s extended-release (ER), abuse-deterrent, oxycodone microsphere-in-capsule product, compared with reformulated OxyContin® (OxyContin).... 
Printer Friendly Version
03/19/14Collegium Pharmaceutical Announces Allowance of New Claims Covering DETERx®, an Abuse-Deterrent, Extended-Release, Technology Platform
Canton, MA – March 19, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that U.S. Patent Application No. 12/965,572 has been allowed for issuance as a new patent by the U.S. Patent and Trademark Office (USPTO). The allowed patent is a formulation patent and covers the DETERx® technology platform. As such, the claims cover multiple products in Collegium’s development pipeline. This is the sixth U.S. patent related to the DETERx® technology platform and is... 
Printer Friendly Version
02/04/14Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx®, its Lead Abuse-Deterrent Development Program
Top-line results anticipated in second quarter 2014Canton, MA – February 4, 2014 – Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the completion of patient enrollment in the pivotal Phase 3 study for Oxycodone DETERx®, its lead development program. The Phase 3 study is a multi-center, double-blind, enriched enrollment, randomized withdrawal, placebo-controlled, safety, tolerability and effic... 
Printer Friendly Version